insulin icodec/semaglutide Icodec + Semaglutide (IcoSema / Kyinsu) A fixed-dose combination of: Basal insulin icodec (ultra-long acting) GLP-1 receptor agonist semaglutide Designed for once-weekly subcutaneous injection Current Status Completed Phase 3 trials (COMBINE Once-a-weekly Long Acting Insulin has

SOX-9, SRY-box transcription factor -9

To improve sleep , the National Sleep Foundation recommends following a sleep schedule (sleeping and getting up at the same time every day), having a relaxing bedtime routine, keeping your bedroom cool and dark, avoiding alcohol and caffeine before bedtime, and exercising regularly

Yes - stopping Mounjaro once a goal weight is reached is a choice many people make

These studies indicate that the butyrate-producing potential of the gut microbiome is depleted already in the prediabetes state, and suggest that replenishment of butyrate producers or butyrate levels might be important to delay or prevent progression to T2D

This study demonstrated the importance of combined GLP-1R and GCGR signalling, as administration of the balanced co-agonist to Glp1r -/- mice led to hyperglycaemia, further demonstrating the necessity of GLP-1R and GCGR co-agonism to minimise this predicted side-effect